Tumoragnosztikus célzott terápia tropomiozin-receptor-tirozinkináz gátlása a gyakorlatban.
Magy Onkol
; 66(1): 29-33, 2022 Mar 28.
Article
en Hu
| MEDLINE
| ID: mdl-35343972
ABSTRACT
Tumor agnostic therapies target specific genomic alterations regardless of tumor localization and histological subtype. Neurotrophic tropomyosin receptor tyrosine kinase (NTRK) gene fusions are important driver gene targets in both pediatric and adult tumors. The first generation TRK inhibitors provide a rapid, effective, and long-lasting antitumor effect with a favorable side effect profile through selective inhibition of TRK fusion proteins. In the case report, we present a case of a young adult female patient with soft tissue sarcoma, in whom the multiple recurrent lower limb tumor disseminated after 3 years, but the systemic treatments used did not show a meaningful therapeutic response. Molecular diagnostic method confirmed the translocation of a very rare driver oncology target, the neurotrophic tropomyosin receptor tyrosine kinase 3 gene. We used convenient and safe inhibitor of tropomyosin receptor tyrosine kinase larotrectinib therapy with good efficacy and excellent quality of life. Larotrectinib was the first and only systemic therapy to which this metastatic soft tissue tumor responded.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tropomiosina
/
Proteínas Tirosina Quinasas Receptoras
/
Neoplasias
Aspecto:
Patient_preference
Límite:
Adult
/
Female
/
Humans
Idioma:
Hu
Revista:
Magy Onkol
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article
País de afiliación:
Hungria